文献速递乳腺癌

激素避孕制剂与青少年及绝经前女性乳腺癌风险

Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项瑞典全国性队列研究纳入2006年1月1日时13至49岁、无相关癌症及手术史的女性,随访至2019年,分析不同激素避孕制剂与乳腺癌风险的关系。结果显示,曾使用任何激素避孕与乳腺癌风险升高相关(HR 1.24,95%CI 1.20-1.28),风险因孕激素成分不同而异,去氧孕烯相关制剂及依托孕烯植入剂风险较高,而醋酸甲羟孕酮注射剂、依托孕烯阴道环和屈螺酮复方口服避孕药未观察到统计学显著风险升高。

要点

  • 曾使用任何激素避孕与乳腺癌风险升高相关(HR 1.24,95%CI 1.20-1.28)。
  • 去氧孕烯相关制剂及依托孕烯植入剂风险较高,左炔诺孕酮复方避孕药风险较低。
  • 醋酸甲羟孕酮注射剂、依托孕烯阴道环和屈螺酮复方口服避孕药未观察到显著风险升高。

核心结论

  • 激素避孕制剂的乳腺癌风险因孕激素成分不同而存在显著差异,可为更知情的避孕处方提供依据。

研究设计与样本

  • 瑞典全国性、基于人群的队列研究,使用关联国家登记数据,纳入2006年1月1日时13至49岁、无乳腺癌、卵巢癌、宫颈癌、子宫癌、双侧卵巢切除术或不孕治疗史的女性,随访2006年至2019年。

主要发现

  • 共纳入2 095 130名青少年女孩和女性,随访21 020 846人年,发生16 385例乳腺癌。
  • 曾使用任何激素避孕与乳腺癌风险升高相关(HR 1.24;95%CI 1.20-1.28),相当于每7752名使用者(95%CI 5350-14 070)增加1例。
  • 复方制剂(HR 1.12;95%CI 1.07-1.17)和仅孕激素制剂(HR 1.21;95%CI 1.17-1.25)均与风险升高相关。
  • 与含左炔诺孕酮的复方口服避孕药(HR 1.09;95%CI 1.03-1.15)和左炔诺孕酮52 mg宫内系统(HR 1.13;95%CI 1.09-1.18)相比,口服去氧孕烯单方制剂(HR 1.18;95%CI 1.13-1.23)、口服去氧孕烯复方制剂(HR 1.19;95%CI 1.08-1.31)及含去氧孕烯活性代谢物依托孕烯的植入剂(HR 1.22;95%CI 1.11-1.35)风险更高。
  • 醋酸甲羟孕酮注射剂、依托孕烯阴道环和屈螺酮复方口服避孕药未观察到统计学显著的风险升高。

临床怎么用

  • 处方激素避孕时应考虑孕激素成分对乳腺癌风险的差异,与患者充分沟通不同制剂的相对风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hormonal contraceptives are widely used but how breast cancer risk differs by hormonal content remains unclear. OBJECTIVE: To estimate the difference in breast cancer risk associated with different hormonal contraceptive formulations. DESIGN, SETTING, AND PARTICIPANTS: This Swedish nationwide, population-based cohort study was conducted using linked national registers. All adolescent girls and women aged 13 to 49 years residing in Sweden as of January 1, 2006, with no history of breast cancer, ovarian cancer, cervical cancer, uterine cancer, bilateral oophorectomy, or infertility treatment were included and followed up from 2006 to 2019. Individuals were censored on meeting an exclusion criterion, reaching age 50 years, or study end, whichever occurred first. Data were analyzed from November 2023 to August 2025. EXPOSURE: Ever use and duration of use of hormonal contraceptives, categorized by hormone formulations and route of administration. MAIN OUTCOMES AND MEASURES: Time-dependent Cox regression was used to estimate hazard ratios (HRs) with 95% CIs for incident cases of in situ and invasive breast cancer. RESULTS: Among 2 095 130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21 020 846 person-years, 16 385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14 070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel's active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users. CONCLUSIONS AND RELEVANCE: Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hadizadeh F, Koteci A, Karlsson T, et al. Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women. JAMA Oncol. 2025. PMID: 41165687. doi:10.1001/jamaoncol.2025.4480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。